UniProtKB/Swiss-Prot P84243: Variant p.Arg9Gly

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 9 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LP/P [Disclaimer: Variants classification is intended for research purposes only, not for clinical and diagnostic use. The label disease variant is assigned according to literature reports on probable disease-association that can be based on theoretical reasons. This label must not be considered as a definitive proof for the pathogenic role of a variant.] The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Arginine (R) to Glycine (G) at position 9 (R9G, p.Arg9Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from large size and basic (R) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description: In BRYLIB1. Any additional useful information about the variant.

Sequence information

Variant position: 9 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 136 The length of the canonical sequence.
Location on the sequence: MARTKQTA R KSTGGKAPRKQLATKAARKS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Initiator methionine	1 – 1	Removed
Chain	2 – 136	Histone H3.3
Region	1 – 43	Disordered
Modified residue	3 – 3	Asymmetric dimethylarginine; by PRMT6; alternate
Modified residue	3 – 3	Citrulline; alternate
Modified residue	4 – 4	Phosphothreonine; by HASPIN and VRK1
Modified residue	5 – 5	Allysine; alternate
Modified residue	5 – 5	N6,N6,N6-trimethyllysine; alternate
Modified residue	5 – 5	N6,N6-dimethyllysine; alternate
Modified residue	5 – 5	N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue	5 – 5	N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue	5 – 5	N6-acetyllysine; alternate
Modified residue	5 – 5	N6-crotonyllysine; alternate
Modified residue	5 – 5	N6-methyllysine; alternate
Modified residue	6 – 6	5-glutamyl dopamine; alternate
Modified residue	6 – 6	5-glutamyl serotonin; alternate
Modified residue	7 – 7	Phosphothreonine; by PKC
Modified residue	9 – 9	Citrulline; alternate
Modified residue	9 – 9	Symmetric dimethylarginine; by PRMT5; alternate
Modified residue	10 – 10	N6,N6,N6-trimethyllysine; alternate
Modified residue	10 – 10	N6,N6-dimethyllysine; alternate
Modified residue	10 – 10	N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue	10 – 10	N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue	10 – 10	N6-acetyllysine; alternate
Modified residue	10 – 10	N6-butyryllysine; alternate
Modified residue	10 – 10	N6-crotonyllysine; alternate
Modified residue	10 – 10	N6-lactoyllysine; alternate
Modified residue	10 – 10	N6-methyllysine; alternate
Modified residue	11 – 11	ADP-ribosylserine; alternate
Modified residue	11 – 11	Phosphoserine; alternate; by AURKB, AURKC, RPS6KA3, RPS6KA4 and RPS6KA5
Modified residue	12 – 12	Phosphothreonine; by PKC
Modified residue	15 – 15	N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue	15 – 15	N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue	15 – 15	N6-acetyllysine; alternate
Modified residue	15 – 15	N6-glutaryllysine; alternate
Modified residue	15 – 15	N6-lactoyllysine; alternate
Modified residue	15 – 15	N6-succinyllysine; alternate
Modified residue	18 – 18	Asymmetric dimethylarginine; by CARM1; alternate
Modified residue	18 – 18	Citrulline; alternate
Modified residue	19 – 19	N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue	19 – 19	N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue	19 – 19	N6-acetyllysine; alternate
Modified residue	19 – 19	N6-butyryllysine; alternate
Modified residue	19 – 19	N6-crotonyllysine; alternate
Modified residue	19 – 19	N6-glutaryllysine; alternate
Modified residue	19 – 19	N6-lactoyllysine; alternate
Modified residue	19 – 19	N6-methyllysine; alternate
Modified residue	24 – 24	N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue	24 – 24	N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue	24 – 24	N6-acetyllysine; alternate
Modified residue	24 – 24	N6-butyryllysine; alternate
Modified residue	24 – 24	N6-crotonyllysine; alternate
Modified residue	24 – 24	N6-glutaryllysine; alternate
Modified residue	24 – 24	N6-lactoyllysine; alternate
Modified residue	24 – 24	N6-methyllysine; alternate
Modified residue	27 – 27	Citrulline
Modified residue	28 – 28	N6,N6,N6-trimethyllysine; alternate
Modified residue	28 – 28	N6,N6-dimethyllysine; alternate
Modified residue	28 – 28	N6-(2-hydroxyisobutyryl)lysine; alternate
Modified residue	28 – 28	N6-(beta-hydroxybutyryl)lysine; alternate
Modified residue	28 – 28	N6-acetyllysine; alternate
Modified residue	28 – 28	N6-crotonyllysine; alternate
Modified residue	28 – 28	N6-glutaryllysine; alternate
Modified residue	28 – 28	N6-lactoyllysine; alternate
Modified residue	28 – 28	N6-methyllysine; alternate
Modified residue	29 – 29	ADP-ribosylserine; alternate
Modified residue	29 – 29	Phosphoserine; alternate; by AURKB, AURKC and RPS6KA5
Lipidation	19 – 19	N6-decanoyllysine
Mutagenesis	6 – 6	Q -> A. Abolished serotonylation by TGM2.
Helix	8 – 10

Literature citations

Histone H3.3 beyond cancer: Germline mutations in Histone 3 Family 3A and 3B cause a previously unidentified neurodegenerative disorder in 46 patients.
Bryant L.; Li D.; Cox S.G.; Marchione D.; Joiner E.F.; Wilson K.; Janssen K.; Lee P.; March M.E.; Nair D.; Sherr E.; Fregeau B.; Wierenga K.J.; Wadley A.; Mancini G.M.S.; Powell-Hamilton N.; van de Kamp J.; Grebe T.; Dean J.; Ross A.; Crawford H.P.; Powis Z.; Cho M.T.; Willing M.C.; Manwaring L.; Schot R.; Nava C.; Afenjar A.; Lessel D.; Wagner M.; Klopstock T.; Winkelmann J.; Catarino C.B.; Retterer K.; Schuette J.L.; Innis J.W.; Pizzino A.; Luettgen S.; Denecke J.; Strom T.M.; Monaghan K.G.; Yuan Z.F.; Dubbs H.; Bend R.; Lee J.A.; Lyons M.J.; Hoefele J.; Guenthner R.; Reutter H.; Keren B.; Radtke K.; Sherbini O.; Mrokse C.; Helbig K.L.; Odent S.; Cogne B.; Mercier S.; Bezieau S.; Besnard T.; Kury S.; Redon R.; Reinson K.; Wojcik M.H.; Ounap K.; Ilves P.; Innes A.M.; Kernohan K.D.; Costain G.; Meyn M.S.; Chitayat D.; Zackai E.; Lehman A.; Kitson H.; Martin M.G.; Martinez-Agosto J.A.; Nelson S.F.; Palmer C.G.S.; Papp J.C.; Parker N.H.; Sinsheimer J.S.; Vilain E.; Wan J.; Yoon A.J.; Zheng A.; Brimble E.; Ferrero G.B.; Radio F.C.; Carli D.; Barresi S.; Brusco A.; Tartaglia M.; Thomas J.M.; Umana L.; Weiss M.M.; Gotway G.; Stuurman K.E.; Thompson M.L.; McWalter K.; Stumpel C.T.R.M.; Stevens S.J.C.; Stegmann A.P.A.; Tveten K.; Voello A.; Prescott T.; Fagerberg C.; Laulund L.W.; Larsen M.J.; Byler M.; Lebel R.R.; Hurst A.C.; Dean J.; Schrier Vergano S.A.; Norman J.; Mercimek-Andrews S.; Neira J.; Van Allen M.I.; Longo N.; Sellars E.; Louie R.J.; Cathey S.S.; Brokamp E.; Heron D.; Snyder M.; Vanderver A.; Simon C.; de la Cruz X.; Padilla N.; Crump J.G.; Chung W.; Garcia B.; Hakonarson H.H.; Bhoj E.J.;
Sci. Adv. 6:0-0(2020)
Cited for: VARIANTS BRYLIB1 GLY-9; SER-9; GLY-16; GLY-18; ILE-23; THR-30; PHE-32; GLU-37; TYR-40; ILE-46; ARG-62; ASN-78; HIS-82; CYS-84; ARG-91; SER-109; LEU-113; VAL-113; LEU-118; ILE-121; LYS-121; ARG-122; LEU-122; ARG-126 AND CYS-129; VARIANTS BRYLIB2 CYS-9; PRO-11; ARG-14; PRO-30; VAL-35; ARG-40; ARG-49; SER-109; VAL-121; ARG-122 AND ARG-126; INVOLVEMENT IN BRYLIB1; INVOLVEMENT IN BRYLIB2;